Nexien Biopharma Inc 's Cash & cash equivalent grew by 534.38 % in the Q3 2025 sequentially, faster than Current Liabilities, this led to improvement in Nexien Biopharma Inc 's Quick Ratio to 0.02, Quick Ratio remained below Nexien Biopharma Inc average.

Within Major Pharmaceutical Preparations industry 456 other companies have achieved higher Quick Ratio than Nexien Biopharma Inc in third quarter 2025. While Quick Ratio total ranking has improved so far during the Q3 2025 to 4005, from total ranking in the second quarter 2024 at 4370.

Explain Quick Ratio?
How much Cash & cash equivalents NXEN�s has?
What are NXEN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NXEN Quick Ratio	(Mar 31 2025) Q3	(Dec 31 2024) Q2	(Sep 30 2024) Q1	(Jun 30 2024) Q4	(Mar 31 2024) Q3
Y / Y Current Liabilities Change	35.1 %	33.84 %	26.78 %	23.82 %	42.77 %
Y / Y Cash & cash equivalent Change	-17.7 %	-50.13 %	-72.58 %	-88.1 %	-81.43 %
Quick Ratio MRQ	0.02	0	0.01	0.01	0.03
NXEN's Total Ranking	# 4005	# 4370	# 4065	# 4079	# 2904
Seq. Current Liabilities Change	8.21 %	6.88 %	8.57 %	7.6 %	7.2 %
Seq. Cash & cash equivalent Change	534.38 %	-73.63 %	18.41 %	-58.45 %	284.38 %

Quick Ratio third quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 457
Healthcare Sector	# 910
Overall Market	# 4005

Quick Ratio Statistics
High	Average	Low
29.77	3.96	0
(Mar 31 2019)		(Dec 31 2024)

Financial Statements
Nexien Biopharma Inc 's Current Liabilities	$ 0 Millions	Visit NXEN's Balance sheet
Nexien Biopharma Inc 's Cash & cash equivalent	$ 0 Millions	Visit NXEN's Balance sheet
Source of NXEN's Sales		Visit NXEN's Sales by Geography

Cumulative Nexien Biopharma Inc 's Quick Ratio

NXEN's Quick Ratio for the trailling 12 Months

NXEN Quick Ratio	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	30.09 %	31.22 %	31.37 %	34.47 %	39.71 %
Y / Y Cash & cash equivalent TTM Growth	-71.58 %	-81.36 %	-87.63 %	-86.54 %	-80.69 %
Quick Ratio TTM	0.01	0.01	0.02	0.03	0.05
Total Ranking TTM	# 3538	# 3518	# 3511	# 3510	# 3378
Seq. Current Liabilities TTM Growth	7.81 %	7.56 %	6.28 %	5.56 %	8.75 %
Seq. Cash & cash equivalent TTM Growth	-8.69 %	-6.02 %	-37.53 %	-46.99 %	-40.11 %

Quick ratio ranking by company, industry and sector >> Back to NXEN Financial Strength Comparisons >> Go to Compare NXEN Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q3 2025 to $0.46 millions, cumulative Quick Ratio remained unchanged at 0.01 below the Nexien Biopharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 455 other companies have achieved higher Quick Ratio than Nexien Biopharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 3518 to 3538.

Explain Quick Ratio?
How much Cash & cash equivalents NXEN�s has?
What are NXEN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 456
Healthcare Sector	# 940
Within the Market	# 3538

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.74	2.56	0.01
(Mar 31 2019)		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2025 MRQ Cash & cash equivalent	Mar 31 2025 MRQ Current Liabilities
Aditxt Inc	0.05	$ 0.502 Millions	$ 11.012 Millions
Lexaria Bioscience Corp	0.04	$ 0.074 Millions	$ 1.793 Millions
Kineta Inc	0.04	$ 0.304 Millions	$ 7.401 Millions
Hcw Biologics Inc	0.04	$ 1.108 Millions	$ 27.142 Millions
Lakeshore Biopharma Co Ltd	0.04	$ 4.391 Millions	$ 113.654 Millions
Northwest Biotherapeutics Inc	0.03	$ 2.779 Millions	$ 83.059 Millions
Abvc Biopharma Inc	0.03	$ 0.217 Millions	$ 6.731 Millions
Lunai Bioworks Inc	0.03	$ 0.923 Millions	$ 28.842 Millions
Cnbx Pharmaceuticals Inc	0.03	$ 0.046 Millions	$ 1.462 Millions
Emmaus Life Sciences Inc	0.02	$ 1.333 Millions	$ 64.915 Millions
Nexien Biopharma Inc	0.02	$ 0.008 Millions	$ 0.459 Millions
Protagenic Therapeutics Inc new	0.01	$ 0.015 Millions	$ 1.077 Millions
Sunshine Biopharma Inc	0.01	$ 0.070 Millions	$ 5.762 Millions
Propanc Biopharma Inc	0.01	$ 0.051 Millions	$ 4.341 Millions
Scorpius Holdings inc	0.01	$ 0.249 Millions	$ 23.140 Millions
Accustem Sciences Inc	0.01	$ 0.036 Millions	$ 3.707 Millions
Celularity Inc	0.00	$ 0.293 Millions	$ 58.690 Millions
Oncotelic Therapeutics Inc	0.00	$ 0.079 Millions	$ 19.485 Millions
Prophase Labs Inc	0.00	$ 0.088 Millions	$ 24.052 Millions

Date modified: 2026-09-08T15:11:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.